Clinical Trial COGADVL0921
Title
A Phase II Study of MLN8237 (IND# 102984), a Selective Aurora A Kinase Inhibitor in Children with Recurrent/Refractory Solid Tumors and Leukemias
Principal Investigator(s)
Details
- Protocol No. COGADVL0921
- Open Date: 09/07/2011
- Staging: Phase II
- Age Group: Children
- Scope: National
- Objective: To determine the objective response rate to MLN8237 in children with relapsed or refractory solid tumors and leukemias, administered once daily for 7 days every 21 days.
- Disease Sites: Neuro-Oncology; Sarcoma; Pediatrics; Leukemia; Pediatric Leukemia; Pediatric Solid Tumors; Germ Cell (Pediatrics); Hepatoblastoma (Pediatrics); Neuroblastoma (Pediatrics); Wilms / Other Kidney (Pediatrics)
- Therapies: None Specified
- Drugs: Alisertib (MLN8237)
- Participating Institutions: Vanderbilt University
- Secondary Protocol No: ADVL0921
Description
None Provided.
Eligibility
Not provided. Please call for more information.
Learn More
- Call toll-free number: 1-800-811-8480
- Use our Online self–referral form
- Print this page for your doctor
You do not have JavaScript enabled. This site works better with JavaScript turned on.
